1
Return

Immunotherapy-Facilitated Conversion Surgery for Biliary Tract Cancer: A Case Series of Long-Term Survivors Following Durvalumab Combined With Gemcitabine and Cisplatin

delete2026-06-11
delete0
PRE
AI
S
Shinichiro Hasegawa
H
Hiroshi Wada
R
Ryoji Takada
M
Masahiko Kubo
M
Masahiro Umezu
S
Shigenori Nagata
K
Keiichiro Honma
Y
Yasunari Fukuda
H
Hisateru Komatsu
K
Kunihito Gotoh
K
Kei Yamamoto
R
Ryota Mori
M
Masatoshi Kitakaze
N
Norihiro Matsuura
Y
Yasunori Masuike
T
Takahito Sugase
Y
Yuki Ushimaru
M
Masaaki Miyo
Y
Yoshitomo Yanagimoto
T
Takashi Kanemura
T
Toshinori Sueda
Y
Yoshinori Kagawa
K
Kazuyoshi Yamamoto
J
Junichi Nishimura
H
Hiroshi Miyata
M
Masayuki Ohue
S
Shogo Kobayashi *
DOI：10.1111/hepr.70210delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Conversion surgery after systemic therapy is gaining attention in biliary tract cancer (BTC), yet evidence under gemcitabine, cisplatin, and durvalumab (GCD) remains scarce.

Journal

Hepatology Research cover
Hepatology Research
IF:
3.4
Papers:
4.2K
Citations:
4.9K

Organization

O
Osaka International Cancer Institute
Scholars:
249
Papers: 107
Citations: 331
U
University of Osaka
Scholars:
4.0K
Papers: 1.3K
Citations: 1
Cited Papers

Cited Papers

Citing Papers

Citing Papers